Current research
In progress
Validation of the ESGO Quality Indicators in Advanced Ovarian Cancer Surgery
A multicentre study analysing over 11,000 patient records to assess the impact of ESGO quality indicators on outcomes and support improvements in care.
Study synopsisAssessment of Quality of Care in Gynaecological Oncology during a national centralization process (Highly Specialized Medicine)
ESGO and Swiss-AGO cooperation: A national study evaluating quality of care during centralisation of gynaecological oncology care in Switzerland.
Study synopsisRole of Secondary Cytoreductive Surgery and Residual Disease in Prognosis and Survival of Patients with Recurrent Epithelial Ovarian Cancer based on BRCA and Homologous Recombination Deficiency Status
This study examines whether secondary cytoreductive surgery (SCS) for recurrent ovarian cancer benefits patients differently based on BRCA mutation and homologous recombination deficiency (HRD) status, since prior data suggest residual disease after surgery matters less for survival in BRCA-mutated tumours than in BRCA wild-type ones.
SHAPE-HIPEC Study: Strategic Hyperthermic intraperitoneal chemotherapy Application Personalized by BRCA/HRD status and maintenance therapy in ovarian cancer
This study uses real-world data to determine whether hyperthermic intraperitoneal chemotherapy (HIPEC) given during interval debulking surgery benefits ovarian cancer patients differently depending on their BRCA/HRD genetic profile, since prior trials give conflicting signals about which tumours respond best.
In Pipeline
Surgical Management and Prognostic Factors of Rare Epithelial Ovarian Cancer with Carcinomatosis
This study focuses on rare, non-high-grade-serous ovarian cancer subtypes (e.g., low-grade serous, clear cell, mucinous, carcinosarcoma), which make up under 10% of cases and are underrepresented in existing research on surgical timing and residual disease thresholds.
Clinical and Prognostic Implication of Epithelial Ovarian Cancer within the Tumor Stage FIGO IV Cohort
This study uses the ESGO database to clarify whether FIGO stage IVA and IVB ovarian cancer carry different prognoses, since prior research on this has been inconsistent, and further examines how metastasis location, surgical approach, and BRCA/HRD status relate to outcomes within these subgroups.
PARAGoN-OV: Prognostic Assessment of Residual disease based on Anatomical distribution, Genetic profiling, and maiNtenance therapy in advanced Ovarian Cancer
This study examines how the size, distribution pattern, and anatomical location of residual disease after ovarian cancer surgery affect survival, and how these effects differ by surgical timing (upfront vs. interval debulking) and molecular profile (BRCA/HRD status).
Comparative Analysis of Clinico-Pathological Profiles, Treatment Approaches, and Oncologic Outcomes in Women with Advanced Epithelial Ovarian Cancer (AEOC) Aged Under 40 Versus Over 40
This study compares clinical profiles, treatment approaches, and outcomes between women under 40 and over 40 with advanced epithelial ovarian cancer, a younger population that is rare, understudied, and faces distinct concerns around fertility and long-term treatment effects.
Identifying the most relevant prognostic parameters in advanced ovarian cancer to provide the basis for a novel and more precise staging system
This study evaluates whether factors not currently included in FIGO staging—such as BRCA/HRD status, residual disease, peritoneal cancer index, and histological subtype—add meaningful prognostic value beyond stage alone, following the precedent set by the recent molecular-informed revision of endometrial cancer staging.
FORCE Study: First-line maintenance therapy's impact On post-Recurrence survival and secondary recurrence
This study investigates whether the type of first-line maintenance therapy (PARP inhibitors, bevacizumab, combination, or none) affects how well patients respond to treatment after their first recurrence, since PARP inhibitor use may induce resistance that carries over to subsequent therapy lines.
ERAS protocol compliance in ESGO accredited centers and its impact on surgical outcome and prognosis
This study evaluates how well ovarian cancer surgery centers adhere to Enhanced Recovery After Surgery (ERAS) guidelines, since compliance is known to be inconsistent despite evidence that ERAS pathways reduce complications and hospital stay.